Verrica Pharmaceuticals Inc
VRCA
Company Profile
Business description
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Contact
44 West Gay Street
Suite 400
West ChesterPA19380
USAT: +1 484 453-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
71
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
We expect the strong earnings momentum at this company to continue, with shares looking fairly valued.
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.90 | 91.60 | -1.00% |
| CAC 40 | 7,881.96 | 94.98 | 1.22% |
| DAX 40 | 23,668.14 | 308.96 | 1.32% |
| Dow JONES (US) | 46,018.32 | 260.42 | 0.57% |
| FTSE 100 | 9,242.28 | 46.62 | 0.51% |
| HKSE | 26,544.85 | 106.34 | 0.40% |
| NASDAQ | 22,261.33 | 72.63 | -0.33% |
| Nikkei 225 | 45,303.43 | 401.16 | 0.89% |
| NZX 50 Index | 13,120.03 | 114.86 | -0.87% |
| S&P 500 | 6,600.35 | 6.41 | -0.10% |
| S&P/ASX 200 | 8,745.20 | 103.30 | -1.17% |
| SSE Composite Index | 3,831.66 | 44.68 | -1.15% |